Group 1 - The company reported a revenue of approximately 686 million RMB for 2025, representing a year-on-year decrease of 3.33% [1] - The net loss attributable to shareholders was approximately 157 million RMB, marking a shift from profit to loss compared to the previous year, with a basic loss per share of 0.15 RMB [1] - The company increased its R&D investment to about 358 million RMB, which constitutes a growing proportion of its revenue [1] Group 2 - The company has made significant progress in its R&D projects, including the completion of patient enrollment for the FDA018 antibody-drug conjugate project ahead of schedule, with over 350 cases enrolled [1] - The company’s subsidiary, Taizhou Fudan Zhangjiang Pharmaceutical Co., Ltd., has been actively supporting the industrialization of antibody-drug conjugate projects, including technology transfer and production process validation [1] - The company adjusted its sales strategy for the drug Liposomal Doxorubicin due to its exclusion from the national procurement list, leading to a gradual reduction in its market retail price starting May 1, 2025, which affected its profit margins [2]

Core Viewpoint - Fudan Zhangjiang has reported significant advancements in its R&D investments and clinical trials, particularly in the fields of antibody-drug conjugates (ADC) and photodynamic therapy drugs, indicating a strong potential for future growth and product diversification [1][2] Group 1: R&D Investments - The company invested approximately 358 million RMB in R&D during the reporting period, with a steady increase in the proportion of R&D spending relative to revenue [1] - R&D funding is primarily directed towards ADC and photodynamic drug development, with multiple pipelines achieving key progress [1] Group 2: ADC Developments - The Phase III clinical trial for the FDA018 ADC targeting triple-negative breast cancer has exceeded its enrollment target, with over 350 participants, and data collection is currently underway [1] - The Phase II clinical study for the FDA022 ADC, aimed at HER2 low-expressing breast cancer, has completed patient enrollment and successfully held a communication meeting with regulatory authorities [1] Group 3: Photodynamic Therapy Developments - The application for marketing authorization of the oral solution of aminolevulinic acid for intraoperative visualization in high-grade glioma has been accepted, which could enhance the company's product portfolio and core competitiveness in the photodynamic therapy sector [1] Group 4: Industrialization Support - Fudan Zhangjiang's wholly-owned subsidiary, Taizhou Fudan Zhangjiang, is providing support for the industrialization of its ADC projects, including technology transfer and production process validation [2] - The commercialization of related products is expected to create new growth points for the company, contributing to its long-term high-quality development [2]

Group 1 - The company Fudan Zhangjiang (01349) reported a revenue of approximately 686 million yuan for 2025, representing a year-on-year decrease of 3.33% [1] - The net loss attributable to shareholders was approximately 157 million yuan, marking a shift from profit to loss compared to the previous year, with a basic loss per share of 0.15 yuan [1] Group 2 - The company actively promoted the progress of R&D projects, with R&D investment accounting for an increasing proportion of revenue, totaling approximately 358 million yuan during the reporting period [2] - The Phase III clinical trial for the FDA018 antibody-drug conjugate for triple-negative breast cancer exceeded enrollment expectations, with over 350 participants enrolled, and data collection is currently underway [2] - The Phase II clinical study for the FDA022 antibody-drug conjugate targeting HER2 low-expressing breast cancer has completed enrollment, and a communication meeting with regulatory authorities was held during the reporting period [2] Group 3 - The company's production and operations remained normal, with no changes in the main types of drugs sold [3] - Due to the inclusion of Doxorubicin Liposome Injection in the national procurement catalog, the company's product, Liposome Doxorubicin, was not selected, prompting a strategic adjustment in its sales approach, including a gradual price reduction starting May 1, 2025, which led to a decrease in profit margins [3]

Performance Forecast - The company expects a net loss attributable to shareholders for the year 2025, estimated between RMB -180 million and RMB -120 million compared to the previous year [1] - The net profit attributable to shareholders, excluding non-recurring gains and losses, is projected to be between RMB -200 million and RMB -140 million for 2025 [1] Previous Year Performance - In the previous year, the total profit was RMB 5.4579 million, with a net profit attributable to shareholders of RMB 39.7339 million [1] - The net profit attributable to shareholders, excluding non-recurring gains and losses, was RMB 514.52 million [1] - Earnings per share for the previous year were RMB 0.04 [1] Reasons for Performance Change - The company has increased its R&D investment, which now constitutes a higher percentage of revenue, with approximately RMB 350 million invested during the reporting period [2] - Significant progress has been made in clinical trials, including the completion of patient enrollment for the FDA018 antibody-drug conjugate project ahead of schedule, with over 350 cases enrolled [1][2] - The company has adjusted its sales strategy for the liposomal doxorubicin injection product due to its inclusion in the national procurement catalog, leading to a profit contribution decrease of approximately RMB 100 million compared to the previous year [2]

Core Viewpoint - Fudan Zhangjiang Biopharmaceutical Co., Ltd. has received acceptance for its drug application for a powder oral solution of Ammonium Pentanoate Hydrochloride, aimed at visualizing malignant tissues during surgery for adult patients with high-grade malignant glioma [1] Group 1 - The drug application was accepted by the National Medical Products Administration, indicating progress in the regulatory process [1] - The clinical trial application for the drug was accepted in December 2023, with verification clinical research set to start in June 2024 [1] - The clinical research for the drug has been completed, leading to the recent acceptance of the drug registration application [1]

Group 1 - The company expects to record an unaudited net loss attributable to the parent company of approximately RMB 120 million to RMB 180 million for the fiscal year ending December 31, 2025, compared to an audited net profit of RMB 39.73 million in 2024 [1] - The company is actively advancing its R&D projects, with R&D expenditure accounting for an increasing proportion of revenue. The Phase III clinical trial for the FDA018 antibody-drug conjugate has exceeded its enrollment target, with over 350 cases enrolled [1] - The company’s subsidiary has been supporting the industrialization of antibody-drug conjugates (ADC), including technology transfer and production process validation [1] Group 2 - The company’s photodynamic drug development projects are progressing as planned, with the registration application for a powder for oral solution of Amifostine for high-grade glioma visualization accepted [2] - R&D expenditure for the reporting period was approximately RMB 350 million [2] - The company adjusted its sales strategy for the product "Li Baoduo" due to changes in market competition and the inclusion of Doxorubicin Liposome Injection in the national centralized procurement directory, leading to a profit contribution decrease of approximately RMB 100 million compared to the same period last year [2]

Summary of Key Points Core Viewpoint - Fudan Zhangjiang (01349) expects a net loss attributable to shareholders of approximately RMB 120 million to RMB 180 million for the year ending December 31, 2025, compared to a net profit of RMB 39.73 million for 2024 [1] Group Performance and R&D Progress - The company is actively advancing its R&D projects, with R&D expenditure as a percentage of revenue continuously increasing. During the reporting period, the Phase III clinical trial for the FDA018 antibody-drug conjugate (anti-Trop2 antibody conjugate SN38 project) was completed ahead of schedule, with over 350 cases enrolled [2] - The company plans to submit a listing application as soon as the data results are collected. The Phase II clinical study for the FDA022 antibody-drug conjugate (anti-HER2 antibody conjugate BB05 project) has completed enrollment, and a clinical discipline communication meeting (EOP2 meeting) with regulators was held during the reporting period [2] - The wholly-owned subsidiary, Taizhou Fudan Zhangjiang Pharmaceutical Co., Ltd., has been supporting the industrialization of the company's antibody-drug conjugate (ADC) R&D projects, including commercial-scale production technology transfer and production process validation [2] - The development of photodynamic drug projects is progressing as planned, with the application for drug registration for the oral solution of ammonium pentobarbital for intraoperative visualization in high-grade glioma having been accepted [2] - R&D investment during the reporting period was approximately RMB 350 million [2] Sales Strategy Adjustments - In 2024, the doxorubicin liposome injection was included in the national centralized procurement directory, but the company's product, Liposome Doxorubicin, was not selected. Consequently, the company adjusted its sales strategy for this product, including a gradual reduction in market retail prices starting May 1, 2025 [3] - This adjustment led to a corresponding decrease in the profit margin of Liposome Doxorubicin, with a year-on-year reduction in profit contribution of approximately RMB 100 million compared to the same period last year [3]

Core Viewpoint - Fudan Zhangjiang (01349) expects a net loss attributable to shareholders of approximately RMB 120 million to RMB 180 million for the year ending December 31, 2025, compared to a net profit of RMB 39.73 million for 2024 [1] Group 1: Financial Performance - The company anticipates a net loss of approximately RMB 140 million to RMB 200 million when excluding non-recurring gains and losses, compared to a net profit of RMB 5.1452 million for 2024 [1] - The projected net loss reflects a significant decline in financial performance compared to the previous year [1] Group 2: Research and Development - The company is actively advancing its R&D projects, with R&D expenditure rising as a percentage of revenue; approximately RMB 350 million was invested in R&D during the reporting period [2] - The Phase III clinical trial for the FDA018 antibody-drug conjugate for triple-negative breast cancer has exceeded its enrollment target, with over 350 cases enrolled [2] - The company’s subsidiary has been supporting the industrialization of antibody-drug conjugates (ADC), including technology transfer and production process validation [2] Group 3: Market Strategy Adjustments - In 2024, the company's Doxorubicin Liposome Injection was included in the national procurement list, leading to a strategic adjustment in sales for the product "Ribaodu," including a gradual price reduction starting May 1, 2025 [3] - The profit contribution from "Ribaodu" decreased by approximately RMB 100 million compared to the same period last year due to the new procurement rules and market competition [3]

Group 1 - The company expects to record an unaudited net loss attributable to the parent company of approximately RMB 120 million to RMB 180 million for the fiscal year ending December 31, 2025, compared to an audited net profit of RMB 39.73 million in 2024 [1] - The company is actively advancing its R&D projects, with R&D expenditure accounting for an increasing proportion of revenue. The Phase III clinical trial for the FDA018 antibody-drug conjugate has exceeded its enrollment target, with over 350 cases enrolled [1] - The company’s subsidiary is supporting the industrialization of antibody-drug conjugates (ADC) by conducting commercial-scale production technology transfers and process validations [1] Group 2 - The company’s photodynamic drug development projects are progressing as planned, with the application for the registration of a powder for oral solution of Amifostine for intraoperative visualization of high-grade gliomas accepted [2] - The company’s R&D expenditure for the reporting period was approximately RMB 350 million [2] - The product Liposomal Doxorubicin was included in the national centralized procurement directory for the first time in 2024, leading to a corresponding adjustment in sales strategy and a decrease in profit contribution of approximately RMB 100 million compared to the same period last year [2]

Core Viewpoint - Fudan Zhangjiang's application for the oral solution powder of hydrochloride aminolevulinic acid for visualizing malignant tissue during surgery for adult high-grade glioma patients has been accepted by the National Medical Products Administration [1] Group 1: Product Information - The product is designed to assist in the surgical treatment of brain gliomas by providing fluorescence guidance to indicate tumor margins [1] - It aims to help surgeons accurately locate and guide the resection area while preserving healthy tissue [1] Group 2: Clinical Benefits - The use of this product is expected to improve the complete resection rate of tumors [1] - It may reduce postoperative neurological deficits and enhance the quality of life for patients [1] - The ultimate goal is to extend the survival period of patients undergoing surgery for high-grade gliomas [1]